亚洲国产欧美精品一区二区三区,亚洲欧美在线免费观看,51国产午夜精品免费视频,欧美特黄视频在线观看,日韩欧美精品在线视频,99视频精品国在线视频艾草,97精品视频在线观看视频app,久久99精品久久久久久,久久精品99久久香蕉国产色戒

Research and Development 科研管線

納基奧侖賽認(rèn)證醫(yī)療機構(gòu)名單創(chuàng)新支付研發(fā)管線學(xué)術(shù)發(fā)表

發(fā)表時間：2022/11/14 來源：Blood - 2022 ASH Annual Meeting Abstract

Structural Optimization of Dual-Target CD22/CD19 CAR-T and Its Anti-Tumor Effects on B Cell Malignancies
發(fā)表時間：2022/11/14 來源：Blood - 2022 ASH Annual Meeting Abstract

CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma:Long-Term Results of a Pilot Prospective Clinical Study
發(fā)表時間：2022/03/21 來源：Experimental Hematology & Oncology

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
發(fā)表時間：2021/11/04 來源：Blood - 2021 ASH Annual Meeting Abstract

CNCT19 for Treatment of Patients with Relapsed Refractory B-Cell AcuteLymphoblastic Leukemia (r/r B-cell ALL) in Children and Adults
發(fā)表時間：2020/09/06 來源：Journal of Hematology & Oncology

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
發(fā)表時間：2020/09/04 來源：Blood - 2020 ASH Annual Meeting Abstract

Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

1 2 3

我們的目標(biāo) 專注細(xì)胞治療領(lǐng)航健康未來